Cargando…
Major adverse kidney events predict reduced survival in ventricular assist device supported patients
AIMS: There is limited data describing major adverse kidney events (MAKE) in patients supported with ventricular assist devices (VAD). We aim to describe the association between MAKE and survival, risk factors for MAKE, and renal trajectory in VAD supported patients. METHODS AND RESULTS: We conducte...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682875/ https://www.ncbi.nlm.nih.gov/pubmed/37712126 http://dx.doi.org/10.1002/ehf2.14533 |
_version_ | 1785151071505612800 |
---|---|
author | Barua, Sumita Conte, Sean M. Cherrett, Callum Kearney, Katherine L. Robson, Desiree Bragg, Christopher Macdonald, Peter S. Muthiah, Kavitha Hayward, Christopher S. |
author_facet | Barua, Sumita Conte, Sean M. Cherrett, Callum Kearney, Katherine L. Robson, Desiree Bragg, Christopher Macdonald, Peter S. Muthiah, Kavitha Hayward, Christopher S. |
author_sort | Barua, Sumita |
collection | PubMed |
description | AIMS: There is limited data describing major adverse kidney events (MAKE) in patients supported with ventricular assist devices (VAD). We aim to describe the association between MAKE and survival, risk factors for MAKE, and renal trajectory in VAD supported patients. METHODS AND RESULTS: We conducted a single‐centre retrospective analysis of consecutive VAD implants between 2010 and 2019. Baseline demographics, biochemistry, and adverse events were collected for the duration of VAD support. MAKE was defined as the first event to occur of sustained drop (>50%) in estimated glomerular filtration rate (eGFR), progression to stage V chronic kidney disease, initiation or continuation of renal replacement therapy beyond implant admission or death on renal replacement therapy at any time. One‐hundred and seventy‐three patients were included, median age 56.8 years, 18.5% female, INTERMACS profile 1 or 2 in 75.1%. Thirty‐seven patients experienced MAKE. On multivariate analysis, post‐implant clinical right ventricular failure and the presence of chronic haemolysis, defined by the presence of schistocytes on blood film analysis, were significantly associated with increased risk of MAKE (adjusted odds ratio 9.88, P < 0.001 and adjusted odds ratio 3.33, P = 0.006, respectively). MAKE was associated with reduced survival (hazard ratio 4.80, P < 0.001). Patients who died or experienced MAKE did not demonstrate the expected transient 3‐month improvement in eGFR, seen in other cohorts. CONCLUSIONS: MAKE significantly impacts survival. In our cohort, MAKE was predicted by post‐implant right ventricular failure and chronic haemolysis. The lack of early eGFR improvement on VAD support may indicate higher risk for MAKE. |
format | Online Article Text |
id | pubmed-10682875 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106828752023-11-30 Major adverse kidney events predict reduced survival in ventricular assist device supported patients Barua, Sumita Conte, Sean M. Cherrett, Callum Kearney, Katherine L. Robson, Desiree Bragg, Christopher Macdonald, Peter S. Muthiah, Kavitha Hayward, Christopher S. ESC Heart Fail Original Articles AIMS: There is limited data describing major adverse kidney events (MAKE) in patients supported with ventricular assist devices (VAD). We aim to describe the association between MAKE and survival, risk factors for MAKE, and renal trajectory in VAD supported patients. METHODS AND RESULTS: We conducted a single‐centre retrospective analysis of consecutive VAD implants between 2010 and 2019. Baseline demographics, biochemistry, and adverse events were collected for the duration of VAD support. MAKE was defined as the first event to occur of sustained drop (>50%) in estimated glomerular filtration rate (eGFR), progression to stage V chronic kidney disease, initiation or continuation of renal replacement therapy beyond implant admission or death on renal replacement therapy at any time. One‐hundred and seventy‐three patients were included, median age 56.8 years, 18.5% female, INTERMACS profile 1 or 2 in 75.1%. Thirty‐seven patients experienced MAKE. On multivariate analysis, post‐implant clinical right ventricular failure and the presence of chronic haemolysis, defined by the presence of schistocytes on blood film analysis, were significantly associated with increased risk of MAKE (adjusted odds ratio 9.88, P < 0.001 and adjusted odds ratio 3.33, P = 0.006, respectively). MAKE was associated with reduced survival (hazard ratio 4.80, P < 0.001). Patients who died or experienced MAKE did not demonstrate the expected transient 3‐month improvement in eGFR, seen in other cohorts. CONCLUSIONS: MAKE significantly impacts survival. In our cohort, MAKE was predicted by post‐implant right ventricular failure and chronic haemolysis. The lack of early eGFR improvement on VAD support may indicate higher risk for MAKE. John Wiley and Sons Inc. 2023-09-15 /pmc/articles/PMC10682875/ /pubmed/37712126 http://dx.doi.org/10.1002/ehf2.14533 Text en © 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Barua, Sumita Conte, Sean M. Cherrett, Callum Kearney, Katherine L. Robson, Desiree Bragg, Christopher Macdonald, Peter S. Muthiah, Kavitha Hayward, Christopher S. Major adverse kidney events predict reduced survival in ventricular assist device supported patients |
title | Major adverse kidney events predict reduced survival in ventricular assist device supported patients |
title_full | Major adverse kidney events predict reduced survival in ventricular assist device supported patients |
title_fullStr | Major adverse kidney events predict reduced survival in ventricular assist device supported patients |
title_full_unstemmed | Major adverse kidney events predict reduced survival in ventricular assist device supported patients |
title_short | Major adverse kidney events predict reduced survival in ventricular assist device supported patients |
title_sort | major adverse kidney events predict reduced survival in ventricular assist device supported patients |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682875/ https://www.ncbi.nlm.nih.gov/pubmed/37712126 http://dx.doi.org/10.1002/ehf2.14533 |
work_keys_str_mv | AT baruasumita majoradversekidneyeventspredictreducedsurvivalinventricularassistdevicesupportedpatients AT conteseanm majoradversekidneyeventspredictreducedsurvivalinventricularassistdevicesupportedpatients AT cherrettcallum majoradversekidneyeventspredictreducedsurvivalinventricularassistdevicesupportedpatients AT kearneykatherinel majoradversekidneyeventspredictreducedsurvivalinventricularassistdevicesupportedpatients AT robsondesiree majoradversekidneyeventspredictreducedsurvivalinventricularassistdevicesupportedpatients AT braggchristopher majoradversekidneyeventspredictreducedsurvivalinventricularassistdevicesupportedpatients AT macdonaldpeters majoradversekidneyeventspredictreducedsurvivalinventricularassistdevicesupportedpatients AT muthiahkavitha majoradversekidneyeventspredictreducedsurvivalinventricularassistdevicesupportedpatients AT haywardchristophers majoradversekidneyeventspredictreducedsurvivalinventricularassistdevicesupportedpatients |